Histamine H1 receptor antagonists - Pipeline Insight, 2022
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Histamine H1 Receptor Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Histamine H1 Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Histamine H1 Receptor Antagonists: Overview
Histamine and its receptors (H1R–H4R) play a crucial and significant role in the development of various allergic diseases. H1R are expressed in many cells, including mast cells, and are involved in Type 1 hypersensitivity reactions. Activation of the H1 receptor increases vascular permeability, stimulates sensory nerves of airways, and promotes chemotaxis of eosinophils, so can cause sneezing, nasal congestion and rhinorrhea. The H1 receptor is widely distributed in the periphery, notably smooth muscle, where it stimulates contraction (vasoconstriction). It is also found in the adrenal medulla, vascular endothelium and heart and throughout the CNS, including the cerebral cortex, spinal cord and cerebellum. H1R-antagonists act as highly effective inverse agonists of H1R, which reduce basal activity of the receptor and therefore are expected to interfere with the key molecular switches involved in the GPCR activation mechanism.
Report Highlights
This segment of the Histamine H1 Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Histamine H1 Receptor Antagonists Emerging Drugs
Further product details are provided in the report……..
Histamine H1 Receptor Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Histamine H1 Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
Histamine H1 Receptor Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Histamine H1 Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Histamine H1 Receptor Antagonists drugs.
Histamine H1 Receptor Antagonists Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Histamine H1 Receptor Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Histamine H1 Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Histamine H1 Receptor Antagonists: Overview
Histamine and its receptors (H1R–H4R) play a crucial and significant role in the development of various allergic diseases. H1R are expressed in many cells, including mast cells, and are involved in Type 1 hypersensitivity reactions. Activation of the H1 receptor increases vascular permeability, stimulates sensory nerves of airways, and promotes chemotaxis of eosinophils, so can cause sneezing, nasal congestion and rhinorrhea. The H1 receptor is widely distributed in the periphery, notably smooth muscle, where it stimulates contraction (vasoconstriction). It is also found in the adrenal medulla, vascular endothelium and heart and throughout the CNS, including the cerebral cortex, spinal cord and cerebellum. H1R-antagonists act as highly effective inverse agonists of H1R, which reduce basal activity of the receptor and therefore are expected to interfere with the key molecular switches involved in the GPCR activation mechanism.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Histamine H1 Receptor Antagonists R&D. The therapies under development are focused on novel approaches for Histamine H1 Receptor Antagonists.
This segment of the Histamine H1 Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Histamine H1 Receptor Antagonists Emerging Drugs
- TNX-102 SL: Tonix Pharmaceuticals
- Flunarizine: Xenon Pharmaceuticals
Further product details are provided in the report……..
Histamine H1 Receptor Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Histamine H1 Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Histamine H1 Receptor Antagonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Histamine H1 Receptor Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Histamine H1 Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Histamine H1 Receptor Antagonists drugs.
Histamine H1 Receptor Antagonists Report Insights
- Histamine H1 Receptor Antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Histamine H1 Receptor Antagonists drugs?
- How many Histamine H1 Receptor Antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Histamine H1 Receptor Antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Histamine H1 Receptor Antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Histamine H1 Receptor Antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Otsuka Pharmaceutical
- Tonix Pharmaceuticals
- Gedeon Richter
- JDP Therapeutics
- Xenon Pharmaceuticals
- FAES Farma
- Hyundai Pharmaceutical
- Lohmann Therapie-Systeme
- Akari Therapeutics
- Aripiprazole
- TNX-102 SL
- Cariprazine
- JDP-205
- Flunarizine
- Bilastine
- HDDO-1801
- Asenapine transdermal patch
- Votucalis
Introduction
Executive Summary
Histamine H1 Receptor Antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Histamine H1 Receptor Antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Histamine H1 Receptor Antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Histamine H1 Receptor Antagonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
TNX-102 SL: Tonix Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Flunarizine: Xenon Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Votucalis: Akari Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Histamine H1 Receptor Antagonists Key Companies
Histamine H1 Receptor Antagonists Key Products
Histamine H1 Receptor Antagonists- Unmet Needs
Histamine H1 Receptor Antagonists- Market Drivers and Barriers
Histamine H1 Receptor Antagonists- Future Perspectives and Conclusion
Histamine H1 Receptor Antagonists Analyst Views
Histamine H1 Receptor Antagonists Key Companies
Appendix
Executive Summary
Histamine H1 Receptor Antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Histamine H1 Receptor Antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Histamine H1 Receptor Antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Histamine H1 Receptor Antagonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
TNX-102 SL: Tonix Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Flunarizine: Xenon Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Votucalis: Akari Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Histamine H1 Receptor Antagonists Key Companies
Histamine H1 Receptor Antagonists Key Products
Histamine H1 Receptor Antagonists- Unmet Needs
Histamine H1 Receptor Antagonists- Market Drivers and Barriers
Histamine H1 Receptor Antagonists- Future Perspectives and Conclusion
Histamine H1 Receptor Antagonists Analyst Views
Histamine H1 Receptor Antagonists Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Histamine H1 Receptor Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Histamine H1 Receptor Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Histamine H1 Receptor Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Histamine H1 Receptor Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products